Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Priming Clear all
Active, not recruiting Phase 1 Interventional

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT05743595
View directory record Official record
Conditions
Unmethylated Glioblastoma
Interventions
Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation device
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

NCT00963872
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
cyclophosphamide, fludarabine phosphate, Total body irradiation, Umbilical cord blood unit with C3a fragment, Unmanipulated UCB Unit
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1 Interventional Results available

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C), Cellectra 2000
Drug · Radiation · Device
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting No phase listed Observational

Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial

NCT06751355
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
SkinScan3D camera
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

NCT02296541
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

NCT02598388
View directory record Official record
Conditions
Hemorrhagic Fever, Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 70 Years
Enrollment
578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038
View directory record Official record
Conditions
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
Interventions
Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Not applicable Interventional

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

NCT06296368
View directory record Official record
Conditions
Hematologic Malignancies, Lymphoma, Multiple Myeloma, Leukemia, Blood Cancers
Interventions
Preference Reporting to Improve Management and Experience (PRIME)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1 Interventional

Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer

NCT01386346
View directory record Official record
Conditions
Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Interventions
Azacitidine, Oxaliplatin, Epirubicin, Capecitabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

NCT00389610
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GVAX pancreas vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity

NCT05107908
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Active Implicit Priming, Control Implicit Priming, Food Exposure Task
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Smartphone App to Improve Physical Activity

NCT03417440
View directory record Official record
Conditions
Sedentary Lifestyle
Interventions
Physical Activity (PA) Tracker App, On Your Feet, Coach Me, Proof Positive
Other
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 84 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Glendale, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 17, 2026, 10:20 PM EDT
Active, not recruiting Phase 3 Interventional

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

NCT03091660
View directory record Official record
Conditions
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Interventions
BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
174
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1Phase 2 Interventional

Study of INKmune in Patients With mCRPC (CaRe Prostate)

NCT06056791
View directory record Official record
Conditions
Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
Interventions
INKmune
Biological
Lead sponsor
Inmune Bio, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Las Vegas, Nevada • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®

NCT00258895
View directory record Official record
Conditions
Diphtheria, Tetanus, Pertussis
Interventions
DAPTACEL®: DTaP
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
649 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
22
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 17, 2026, 10:20 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations

NCT06713577
View directory record Official record
Conditions
Dental Prosthesis Failure, Dental Prosthesis Complication
Interventions
CEREC Cercon 4D
Device
Lead sponsor
Dentsply Sirona Implants and Consumables
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Not listed Phase 1 Interventional

Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma

NCT00016055
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
lymphokine-activated killer cells, temozolomide
Biological · Drug
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting No phase listed Observational

A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

NCT07635316
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 110 Years
Enrollment
4,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms of Impaired Brain Blood Flow With Aging

NCT03775382
View directory record Official record
Conditions
Aging
Interventions
Ascorbic Acid, Normal Saline
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 79 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 2 Interventional

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Talquetamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects

NCT02053935
View directory record Official record
Conditions
Hyperglycemia, Sepsis
Interventions
Dopamine
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Intra Uterine Device Insertion in Nulliparous Women

NCT01422226
View directory record Official record
Conditions
Contraception
Interventions
Misoprostol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 17, 2026, 10:20 PM EDT